Home > Oncology > SABCS 2021 > HR-positive/HER2-negative Breast Cancer > Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment

Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment

Presented By
Prof. Michael Gnant, Medical University of Vienna, Austria

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 3, PALLAS
Although adjuvant therapy with CDK4/6-inhibitors has shown to benefit patients with advanced/metastatic hormone receptor (HR)-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial showed no benefit of adjuvant palbociclib for patients with early HR-positive/HER2-negative breast cancer. The use of CDK4/6 inhibitors combined with endocrine therapy is a standard of care for advanced HR-positive/HER2-negative breast cancer, supporting the rationale to study CDK4/6 inhibition in the early breast cancer setting. PALLAS (NCT02513394) is a randomised, phase 3, open-label trial in which patients with stage 2–3 HR-positive/HER2-negative early breast cancer were randomised to receive either 2 years of palbociclib with adjuvant endocrine therapy or endocrine therapy alone. A total of 5,761 patients (median age 52 years, range 22–90) were enroll...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on